Literature DB >> 31403928

Evolution of the residual risk of HBV, HCV and HIV transmission through blood transfusion in the Region of Valencia, Spain, during a 15-year period (2003-2017).

Carlos López-Menchero1, Manuel Alvarez2, Pascual Fernández3, María Guzmán2, María I Ortiz-de-Salazar4, Cristina Arbona2.   

Abstract

BACKGROUND: Towards the end of the 20th century, transfusion-transmitted viral infections (TTVI) represented a huge problem for public health. From the beginning of the screening of blood donations, this risk has decreased to the point that it is no longer possible to measure it directly and it is necessary to use mathematical models. Using one of these models, the aim of this study was to analyse the evolution of the residual risk of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) transmission through blood transfusion from 2003 to 2017 in the Region of Valencia, Spain.
MATERIALS AND METHODS: Using data from the Blood Transfusion Centre of the Valencian Community, the incidence rate in donors and the residual risk were calculated for each agent and year by applying the most updated version of the incidence/window period model. For the set of the three viruses, these magnitudes were calculated as the algebraic sum of the specifics ones for each of them. The evolution of both magnitudes was analysed by the Mann-Kendall trend test and the Sen estimation of trend slope.
RESULTS: The residual risks obtained vary depending on the agent and the year. Considering the three viruses jointly, they range from 1 per 360,380 to 1 per 44,715 donations. During the study period, there was a statistically significant downward trend in the incidence rate of HBV (p<0.05, trend slope -0.88), the residual risk of HBV (p<0.0005, slope -0.98), and the joint residual risk for the three viruses (p<0.0001, slope -0.99). DISCUSSION: The current risk of TTVI is very low in the Region of Valencia. In the last 15 years, there has been a reduction in the donor incidence rate and in the residual risk for the case of HBV; such a reduction cannot be confirmed for HCV and HIV. Consideration of the three viruses jointly confirms a reduction in the residual risk; we are unable to establish whether the evolution of the joint incidence rate has contributed to this reduction or whether it is due only to the shortening of window periods.

Entities:  

Mesh:

Year:  2019        PMID: 31403928      PMCID: PMC6917534          DOI: 10.2450/2019.0058-19

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  16 in total

1.  Lung-cancer mortality as related to residence and smoking histories. I. White males.

Authors:  W HAENSZEL; D B LOVELAND; M G SIRKEN
Journal:  J Natl Cancer Inst       Date:  1962-04       Impact factor: 13.506

Review 2.  Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion.

Authors:  Steven H Kleinman; Nico Lelie; Michael P Busch
Journal:  Transfusion       Date:  2009-07-21       Impact factor: 3.157

3.  Refining the risk estimate for transfusion-transmission of occult hepatitis B virus.

Authors:  C R Seed; P Kiely; V C Hoad; A J Keller
Journal:  Vox Sang       Date:  2016-08-26       Impact factor: 2.144

4.  A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.

Authors:  Michael P Busch; Simone A Glynn; Susan L Stramer; D Michael Strong; Sally Caglioti; David J Wright; Brandee Pappalardo; Steven H Kleinman
Journal:  Transfusion       Date:  2005-02       Impact factor: 3.157

5.  Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing.

Authors:  M Alvarez do Barrio; R González Díez; J M Hernández Sánchez; S Oyonarte Gómez
Journal:  Euro Surveill       Date:  2005-02

6.  Prevalence, incidence and residual risk of transfusion-transmitted hepatitis C virus and human immunodeficiency virus after the implementation of nucleic acid testing in Italy: a 7-year (2009-2015) survey.

Authors:  Claudio Velati; Luisa Romanò; Vanessa Piccinini; Giuseppe Marano; Liviana Catalano; Simonetta Pupella; Giuseppina Facco; Ilaria Pati; Maria Elena Tosti; Stefania Vaglio; Giuliano Grazzini; Alessandro Zanetti; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2018-06-26       Impact factor: 3.443

7.  Hepatitis B virus testing by minipool nucleic acid testing: does it improve blood safety?

Authors:  Susan L Stramer; Edward P Notari; David E Krysztof; Roger Y Dodd
Journal:  Transfusion       Date:  2013-04-23       Impact factor: 3.157

8.  Current incidence and residual risk of hepatitis B infection among blood donors in the United States.

Authors:  Shimian Zou; Susan L Stramer; Edward P Notari; Mary C Kuhns; David Krysztof; Fatemeh Musavi; Chyang T Fang; Roger Y Dodd
Journal:  Transfusion       Date:  2009-08       Impact factor: 3.157

9.  Estimating the incubation time distribution and expected number of cases of transfusion-associated acquired immune deficiency syndrome.

Authors:  J D Kalbfleisch; J F Lawless
Journal:  Transfusion       Date:  1989-10       Impact factor: 3.157

Review 10.  Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis.

Authors:  Rebecca F Baggaley; Marie-Claude Boily; Richard G White; Michel Alary
Journal:  AIDS       Date:  2006-04-04       Impact factor: 4.177

View more
  6 in total

1.  Covid-19 Pandemic: What Changes for Dentists and Oral Medicine Experts? A Narrative Review and Novel Approaches to Infection Containment.

Authors:  Maria Eleonora Bizzoca; Giuseppina Campisi; Lorenzo Lo Muzio
Journal:  Int J Environ Res Public Health       Date:  2020-05-27       Impact factor: 3.390

2.  Prevalence, incidence and residual risk of transfusion transmitted viruses (HBV, HCV and HIV infections) in Lithuanian blood donors from 2004 to 2018: The incidence/window-period model study.

Authors:  Samanta Grubyte; Jurgita Urboniene; Laura Nedzinskiene; Auguste Jelinskaite; Kestutis Zagminas; Arvydas Ambrozaitis; Ligita Jancoriene
Journal:  PLoS One       Date:  2021-02-19       Impact factor: 3.240

3.  Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain.

Authors:  Rocío González; Luisa Barea; Ana Arruga; Alberto Richart; Vicente Soriano
Journal:  Ther Adv Infect Dis       Date:  2020-12-24

4.  Hepatitis B virus infection and its associated factors among medical waste collectors at public health facilities in eastern Ethiopia: a facility-based cross-sectional study.

Authors:  Degu Abate Mengiste; Abebe Tolera Dirbsa; Behailu Hawulte Ayele; Tewodros Tesfa Hailegiyorgis
Journal:  BMC Infect Dis       Date:  2021-02-27       Impact factor: 3.090

5.  Personal Freedom and Public Responsibility: Remaining Questions after First Case of HIV Transmission via Blood Transfusion in North Serbia.

Authors:  Jasmina Grujić; Nevenka Bujandrić; Pavle Banović
Journal:  Healthcare (Basel)       Date:  2022-07-27

Review 6.  Platelet Transfusion: And Update on Challenges and Outcomes.

Authors:  Pilar Solves Alcaina
Journal:  J Blood Med       Date:  2020-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.